Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proposed Proprietary Name Evaluation, August 11, 2011 - Bivigam


Date:                           August 18, 2011
From:                          Alpita Popat, PharmD, MBA, Consumer Safety Officer
                                      CBER/OCBQ/DCM/APLB, HFM-602
Through:                    Lisa L. Stockbridge, Ph.D., Branch Chief
                                      CBER/OCBQ/DCM/APLB, HFM-602
To:                              Pratibha Rana, RPM, OBRR/DBA/RPMB
                                      Charles Maplethorpe, MD, Medical Officer, OBRR/DH/CRB
Subject:                      Re-evaluation of proposed proprietary name Bivigam (IVIG Gammaglobulin)
                                             BLA 125389
Recommendation:      Bivigam proprietary name found Acceptable
Executive Summary:
APLB performed a re-evaluation of the proposed proprietary name Bivigam, an IVIG Gammaglobulin, to determine if any new products were approved since our previous review on February 14, 2011. APLB found that no new products were approved that would change our previous recommendation. APLB recommends that the proposed proprietary name Bivigam be found Acceptable. 
APLB re-reviewed the proprietary name to ensure that our review is within 90 days of approval. The PDUFA goal date for this product is September 3, 2011. There are no newly marked products whose names resembled Bivigam.
APLB recommends that the proposed proprietary name, Bivigam be foundacceptable. 
If you have any questions concerning this review, please contact Alpita Popat, PharmD, MBA, Consumer Safety Officer at 301-827-6329.

Page Last Updated: 01/18/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English